The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Sequencing of BCMA-directed therapies for multiple myeloma
Amrita Krishnan, MD, City of Hope, Duarte, CA, discusses sequencing BCMA-directed therapies for myeloma, favoring CAR T-cell therapy first based on trial data and real-world experience. After CAR-T relapse, other BCMA-directed therapies, like antibody-drug conjugates (ADCs) and bispecifics, can be used. Managing bispecifics involves balancing efficacy and toxicity, with Dr Krishnan predicting that the future may see bispecifics administered for fixed durations rather than until disease progression. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
